Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 102-107

  Villavicencio, A ^a   Goyeneche, A ^b   Telleria, C ^b   Bacallao, K ^c   Gabler, F ^d   Fuentes, A ^d   Vega, M ^e  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

Cell cycle regulators; Endometrium; Polycystic ovarian syndrome; Survival proteins

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; PROTEIN KINASE B; PROTEIN P27; RAS PROTEIN;

ADULT; ARTICLE; CELL CYCLE REGULATION; CLINICAL ARTICLE; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; ENDOMETRIAL HYPERPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; POLYCYSTIC OVARY SYNDROME; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS;

EID: 69249230818     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.033     Document Type: Article

References (48)

1. Nardo L.G., Patchava S., and Laing I. Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. Panminerva Med. 50 (2008) 267-278
2. Hart R. PCOS and infertility. Panminerva Med. 50 (2008) 305-314
3. Balen A. Polycystic ovary syndrome and cancer. Hum. Reprod. Update 7 (2001) 522-525
4. Schmeler K.M., Soliman P.T., Sun C.C., Slomovitz B.M., Gershenson D.M., and Lu K.H. Endometrial cancer in young, normal-weight women. Gynecol. Oncol. 99 (2005) 388-392
5. Pillay O.C., Te Fong L.F., Crow J.C., Benjamin E., Mould T., Atiomo W., et al. The association between polycystic ovaries and endometrial cancer. Hum. Reprod. 21 (2006) 924-929
6. Giudice L.C. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best. Pract. Res. Clin. Endocrinol. Metab. 20 (2006) 235-244
7. Navaratnarajah R., Pillay O.C., and Hardiman P. Polycystic ovary syndrome and endometrial cancer. Semin. Reprod. Med. 26 (2008) 62-71
8. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19 (2004) 41-47
9. Villavicencio A., Bacallao K., Gabler F., Fuentes A., Albornoz J., Casals A., et al. Deregulation of tissue homeostasis in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol. Oncol. 104 (2007) 290-295
10. Chamlian D.L., and Taylor H.B. Endometrial hyperplasia in young women. Obstet. Gynecol. 36 (1970) 659-666
11. Cheung A.P. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet. Gynecol. 98 (2001) 325-331
12. Tingthanatikul Y., Choktanasiri W., Rochanawutanon M., and Weerakeit S. Prevalence and clinical predictors of endometrial hyperplasiain anovulatory women presenting with amenorrhea. Gynecol. Endocrinol. 22 (2006) 101-105
13. Shiozawa T., Li S.F., Nakayama K., Nikaido T., and Fujii S. Relationship between the expression of cyclins/cyclin-dependent kinases and sex-steroid receptors/Ki67 in normal human endometrial glands and stroma during the menstrual cycle. Mol. Hum. Reprod. 2 (1996) 745-752
14. Oshita T., Shigemasa K., Nagai N., and Ohama K. p27, cyclin E, and CDK2 expression in normal and cancerous endometrium. Int. J. Oncol. 21 (2002) 737-743
15. Shiozawa T., Miyamoto T., Kashima H., Nakayama K., Nikaido T., and Konishi I. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23 (2004) 8603-8610
16. Moroy T., and Geisen C. Cyclin E. Int. J. Biochem. Cell. Biol. 36 (2004) 1424-1439
17. Stein G.S., van Wijnen A.J., Stein J.L., Lian J.B., Montecino M., Zaidi S.K., et al. An architectural perspective of cell-cycle control at the G1/S phase cell-cycle transition. J. Cell. Physiol. 209 (2006) 706-710
18. Blagosklonny M.V. Are p27 and p21 cytoplasmic oncoproteins?. Cell Cycle 1 (2002) 391-393
19. Reed S.I. Keeping p27(Kip1) in the cytoplasm: a second front in cancer's war on p27. Cell Cycle 1 (2002) 389-390
20. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8 (2002) 1153-1160
21. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8 (2002) 1145-1152
22. Besson A., Assoian R.K., and Roberts J.M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors?. Nat. Rev. Cancer 4 (2004) 948-955
23. Milde-Langosch K., Bamberger A.M., Goemann C., Rossing E., Rieck G., Kelp B., et al. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J. Cancer Res. Clin. Oncol. 127 (2001) 537-544
24. Shih H.C., Shiozawa T., Kato K., Imai T., Miyamoto T., Uchikawa J., et al. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum. Pathol. 34 (2003) 471-478
25. Tsuda H., Hashiguchi Y., Inoue T., and Yamamoto K. Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 65 (2003) 159-166
26. Ma K., Cheung S.M., Marshall A.J., and Duronio V. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cell Signal. 20 (2008) 684-694
27. Guzeloglu Kayisli O., Kayisli U.A., Luleci G., and Arici A. In vivo and in vitro regulation of Akt activation in human endometrial cells is estrogen dependent. Biol. Reprod. 71 (2004) 714-721
28. Toyofuku A., Hara T., Taguchi T., Katsura Y., Ohama K., and Kudo Y. Cyclic and characteristic expression of phosphorylated Akt in human endometrium and decidual cells in vivo and in vitro. Hum. Reprod. 21 (2006) 1122-1128
29. Tokunaga E., Oki E., Egashira A., Sadanaga N., Morita M., Kakeji Y., et al. Deregulation of the Akt pathway in human cancer. Curr. Cancer Drug Targets 8 (2008) 27-36
30. Coleman M.L., Marshall C.J., and Olson M.F. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 5 (2004) 355-366
31. Hecht J.L., and Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24 (2006) 4783-4791
32. Liu F.S. Molecular carcinogenesis of endometrial cancer. Taiwan. J. Obstet. Gynecol. 46 (2007) 26-32
33. Doll A., Abal M., Rigau M., Monge M., Gonzalez M., Demajo S., et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol. 108 (2008) 221-229
34. Kurman R.J., Kaminski P.F., and Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56 (1985) 403-412
35. Noyes R.W., Hertig A.T., and Rock J. Dating the endometrial biopsy. Am. J. Obstet. Gynecol. 122 (1975) 262-263
36. Lessey B.A., Killam A.P., Metzger D.A., Haney A.F., Greene G.L., and McCarty Jr. K.S. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J. Clin. Endocrinol. Metab. 67 (1988) 334-340
37. Castro A., Johnson M.C., Anido M., Cortinez A., Gabler F., and Vega M. Role of nitric oxide and bcl-2 family genes in the regulation of human endometrial apoptosis. Fertil. Steril. 78 (2002) 587-595
38. Iniguez G., Villavicencio A., Gabler F., Palomino A., and Vega M. Effect of nitric oxide on the expression of insulin-like growth factors and the insulin-like growth factor binding proteins throughout the lifespan of the human corpus luteum. Reproduction 122 (2001) 865-873
39. Tu Z., Gui L., Wang J., Li X., Sun P., and Wei L. Tumorigenesis of K-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. Gynecol. Oncol. 101 (2006) 274-279
40. Testa J.R., and Tsichlis P.N. AKT signaling in normal and malignant cells. Oncogene 24 (2005) 7391-7393
41. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., and Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538-541
42. Villavicencio A., Bacallao K., Avellaira C., Gabler F., Fuentes A., and Vega M. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol. Oncol. 103 (2006) 307-314
43. Lee M.H., and Yang H.Y. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 22 (2003) 435-449
44. Hwang H.C., and Clurman B.E. Cyclin E in normal and neoplastic cell cycles. Oncogene 24 (2005) 2776-2786
45. Bresnahan W.A., Boldogh I., Ma T., Albrecht T., and Thompson E.A. Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ. 7 (1996) 1283-1290
46. Erkanli S., Kayaselcuk F., Kuscu E., Bagis T., Bolat F., Haberal A., et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium, Int. J. Gynecol. Cancer 16 (2006) 1412-1418
47. Shiozawa T., Nikaido T., Nakayama K., Lu X., and Fujii S. Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone. Mol. Hum. Reprod. 4 (1998) 899-905
48. Pestell R.G., Albanese C., Reutens A.T., Segall J.E., Lee R.J., and Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr. Rev. 20 (1999) 501-534